~~<i id='43351E67D3'><strike id='43351E67D3'><tt id='43351E67D3'><pre id='43351E67D3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：knowledge 2025-08-23 05:00:11 - browse：82598

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： CMS should re

focus

explore

knowledge

Wikipedia

focus

leisure time

AdobeThenumberofstrokedeathsworldwideissettoclimb50%tonearly10millionby2050,withmostcasesoccurringin

WSS

FDA approves world's first CRISPR

Analysis of telehealth claims data suggest service duplication

Liquid biopsy for lung cancer is launched by Delfi

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

focus

entertainment

focus

Jerome Adams on the need for new antivirals for Covid

After sickle

Jerome Adams on the need for new antivirals for Covid

What PEPFAR has meant on the ground in Ukraine

Supreme Court strikes down use of affirmative action

Pharma patents targeted by Biden in move to slash drug prices

Drug repurposing or repositioning? The language matters

Physician executives need more than on

Alkermes shareholders re

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

explore

What PEPFAR has meant on the ground in Ukraine

Why sickle cell disease is getting the first CRISPR treatment

AI can decode, harness the power of the humane immune system

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Radiology is caught between AI's potential and concern for patients

3 questions for the future of Biden's cancer moonshot

knowledge

Wikipedia

focus

leisure time